Chet Metcalf
Vice President, Chemistry Head of Research & Development Regeneron Pharmaceuticals
Seminars
Monday 12th October 2026
Pushing the Boundary of Novel Bioconjugate Mechanisms & Design
Monday 12th October 2026
Spotlighting Discovery of Novel Linker Payloads to Set the Path for the Next Wave of Differentiated Antibody Conjugates
12:00 pm
- Breaking down discovery and lessons learned from REGN5093 (METxMET)-M114 biparatopic ADC
- Exploring the Regeneron ProDXd platform for discovery and development of differentiated ADCs
- Assessing novelty and discovery of targeting GPCRs with Antibody Tethered Ligand (ATL) conjugates
Monday 12th October 2026
Summary Panel Discussion: Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation
3:00 pm
At the end of the seminar day, don’t miss this summary panel discussion to discuss, debate and challenge your speakers and ADC peers on the cutting-edge of ADC design, exploring the most promising areas of ADC innovation, benefits against traditional therapies, and hurdles to advance novel conjugates into and through the clinic.
Tuesday 13th October 2026
Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
8:00 am
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
